Abivax is trading 4.3% down now at $99 after September 21, 2026 results showed a €165.9 million first-half net loss, versus €100.8 million a year earlier, alongside sharply higher R&D spending.
- Wedbush cut its price target to $118 from $160 while maintaining a Neutral rating.
- Management reiterated a year-end 2026 obefazimod NDA timeline and runway through Q4 2029, but these positives have not offset earnings-related concerns.